The endorsement is for the first time that an Indian company has achieved FDA clearance in the air-decontamination category
Biomoneta, a healthtech company building advanced air-decontamination technologies, announced that its flagship product Avata Rx, powered by its proprietary ZeBox microbicidal technology, has received approval from the United States Food and Drug Administration (US FDA), marking the first time an Indian company has achieved FDA clearance in the air-decontamination category.
This milestone is not only a validation of India’s deep-tech innovation capabilities but also reinforces the global urgency for clinically validated solutions that combat airborne pathogens, one of the most persistent sources of healthcare-associated infections (HAIs).
The approval is a major endorsement of Biomoneta’s scientific breakthrough and an important inflection point for Beyond Next Ventures India (BNV India), Japan-based early-stage deep-science fund known for backing transformative research-driven startups. BNV’s investment philosophy centers on supporting technologies rooted in deep science, real-world utility, and global scalability, and Biomoneta’s FDA recognition exemplifies this thesis.
Jay Krishnan, Partner-India, Beyond Next Ventures (BNV), said, “Biomoneta represents exactly the kind of deep-science innovation Beyond Next Ventures exists to back- Technologies built on rigorous research, validated in real-world environments, and capable of creating global impact. FDA approval is not just a regulatory milestone, it is a scientific endorsement that places Biomoneta on the world stage. We are proud to support a team turning frontier microbiology into solutions that protect lives and redefine what clean-air technology can achieve.”
Arindam Ghatak, Co-founder and CEO, Biomoneta, further added, “FDA approval for Avata Rx is a powerful validation of nearly a decade of scientific persistence, engineering rigour, and an unwavering belief that clean air should be a fundamental standard of care. This milestone accelerates our mission to bring proven, real-time microbial elimination to healthcare and biotech environments worldwide. We are grateful to partners like Beyond Next Ventures, whose conviction in deep-tech innovation has helped us bring this breakthrough to the global market.”
